Golden Meditech Successfully Listed Taiwan Depositary Receipt on the Taiwan Stock Exchange

Strong First Day Performance Triggered Daily Upper Ceiling Mechanism - Closing at 6.7% above Issue Price

HONG KONG, Jan. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Company," together with its subsidiaries collective as the "Group," 801.HK), China's leading integrated healthcare enterprise, is pleased to announce that the Company has successfully listed its Taiwan Depositary Receipts (TDR: 910801) on the Taiwan Stock Exchange ("TSE") as of today.

Each unit of TDR represents two ordinary shares of the Company, with reference to the closing price on January 14th of HK$1.5 per share, each TDR unit and will be priced at NT$11.2, representing a slight discount from the previous day's close price.  Trading on the first day triggered the TSE’s 7% daily upper ceiling limit, closing at NT$11.95 with 6.7% increase on issue price.

The Group intends to zero-in on the extensive industry experience and competitive advantages of the healthcare industry in Taiwan in addition to opportunities to create greater synergies via collaboration with Taiwan-based entities while targeting, specifically, healthcare professionals and healthcare management talents and to explore the potential markets.

Group Chairman and Chief Executive Officer Mr. Yuen KAM also communicated the Group's objective to enable investors from Taiwan to share with the Group's success stemming from China's medical reforms while enlarging the Company's shareholder base and liquidity through the TDR issue.

Mr. Kam reiterated, "The implementation of ECFA ("Economic Cooperation Framework Agreement") will bring forth greater prospects for symbiotic relationships between industry counterparts on the Mainland and in Taiwan.  We are also confident that the TDR issue will increase public awareness of the Group and help promote the Group's brand image.  This will facilitate our future business initiatives in Taiwan and strengthen our core operations in the Mainland, rendering the move for the TDR Issue in the best interests of the Group and its Shareholders."

The underwriter of the TDR issue, Polaris Securities, also stated that the company is the first "medical device and healthcare services" enterprise to be listed in Taiwan with general market consensus that Golden Meditech encompasses multiple winning strategic focuses, including its leading position and positive outlook on medical devices, hospital management, and medical insurance management with contribution from mainland China's leading umbilical cord blood stem cells storage business.  As a leader in numerous niche markets, the Company is expected to reap immense benefit from mainland China's medical reforms and the immense opportunities brought about by the implementation of ECFA."

Golden Meditech's earnings for the six month interim period ended September 30 2010 has reached HK$162 million with 24% increase, net profit after tax amounted to HK$161 million with 170% increase relative to the previous interim period.  For the financial year ended March 31, 2010, the Company's profit increased by 54% year-on-year with annual revenue of HK$285 million, a gross margin of 60.5% and net profit after tax of HK$123 million.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited is China's leading integrated-healthcare device and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx).  Thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities Golden Meditech has, over the years, established itself as a first-mover in China's healthcare industry with dominant positions in medical devices and healthcare services markets.  Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

For enquiries, please contact: